University System of Maryland

University of Washington

Robert K Ernst

Mark Pelletier

Adeline Hajjar

David R Goodlett

Alison J Scott

Erin M Harberts

Ying Sonia Ting

Yu Chieh “Philip” Kao

The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula

Methods of treating sepsis using anti-sepsis lipid a (ASLA) based therapeutics

Embodiments of the disclosure provide for unique lipooligosaccharide/lipid A-based mimetics for use as adjuvants. Methods of generating lipooligosaccharide/lipid A-based mimetics are provided that utilize recombinantly engineered bacteria to produce the mimetics, including, for example, addition of one or more particular enzymes such as acyltransferases, deacylases, phosphatases, or glycosyltransferases.

Immunotherapeutic potential of modified lipooligosaccharides/lipid A

The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula wherein Rand Rmay be H, OH, protonated phosphate, a phosphate salt, a sugar phosphonate, or a mono-, di- or poly-saccharide, Rmay be OH or a mono-, di- or poly-saccharide, R, R, Rand Rmay be an alkyl or alkenyl chain of up to 13 carbons (for a chain of 16 carbons), and R, R, Rand Rmay be H, OH, or an alkyl or alkenyl ester of up to 16 carbons, or a salt thereof.

Methods of treating sepsis using anti-sepsis lipid A (ASLA) based therapeutics

Methods for identifying fungal species by analysis of fungal membrane lipids, such as glycerophospholipids, sphingolipids and sterols, using mass spectrometry ionization patterns are disclosed.

Methods for identifying fungi

The present invention provides methods for identifying bacteria by analysis of lipid A and/or lipoteichoic acid structure and/or mass spectrometry ionization patterns.

Growing community of inventors

Silver Spring, MD, United States of America

Robert K Ernst